Breaking News

Financial Report: Biogen Idec

April 23, 2014

51% growth driven by MS franchise

Biogen Idec
1Q Revenues:
$2.1 billion (+51%)

1Q Earnings: $480 million (+12%)

Comments: TECFIDERA, recently approved for MS patients in Europe, had revenues of $506 million, comprised of $460 million the U.S. and approximately $46 million outside the U.S. AVONEX revenues increased 2% to $761 million. TYSABRI revenues were up 41% to $441 million due to recording 100% its revenues following the acquisition of complete asset rights in 2Q13. RITUXAN and GAZYVA revenues from an unconsolidated joint business arrangement were $297 million.

blog comments powered by Disqus